Advertisement

Health-Related Quality of Life Related to Toxicity Treatments in Central Nervous System Metastases

  • Tobias WalbertEmail author
  • Erika S. Horta
Chapter

Abstract

Health-related quality of life (HRQoL) is a multidimensional concept that measures how a disease and the treatment of that disease impact a patient’s life. It can also aid in the dialogue between physician and patient. As different therapies have distinct mechanisms, the HRQoL of a patient might be affected in diverse ways depending on the particular side effects that he or she experiences. This chapter discusses the importance of HRQoL related to treatment toxicity, the different tools that are used to measure this outcome, and how different therapeutic modalities impact the patient with central nervous system (CNS) metastases.

Keywords

Central nervous system (CNS) Chemotherapy Health-related quality of life (HRQoL) Immunotherapy Metastasis Outcome Quality of life (QOL) Radiation Surgery 

Notes

Acknowledgments

Funding: Department of Neurosurgery and the Hermelin Brain Tumor Center, Henry Ford Health System.

Conflict of Interest: There are no conflicts of interest to declare.

References

  1. 1.
    Meyers CA, Rock EP, Fine HA. Refining endpoints in brain tumor clinical trials. J Neuro-Oncol. 2012;108(2):227–30.  https://doi.org/10.1007/s11060-012-0813-8.CrossRefGoogle Scholar
  2. 2.
    Habets EJ, Dirven L, Wiggenraad RG, Verbeek-de Kanter A, Lycklama ANGJ, Zwinkels H, Klein M, Taphoorn MJ. Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study. Neuro-Oncology. 2016;18(3):435–44.  https://doi.org/10.1093/neuonc/nov186.CrossRefPubMedGoogle Scholar
  3. 3.
    Castrucci WA, Knisely JP. An update on the treatment of CNS metastases in small cell lung cancer. Cancer J. 2008;14(3):138–46.  https://doi.org/10.1097/PPO.0b013e318172d6e1.CrossRefGoogle Scholar
  4. 4.
    Peters S, Bexelius C, Munk V, Leighl N. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev. 2016;45:139–62.  https://doi.org/10.1016/j.ctrv.2016.03.009.CrossRefPubMedGoogle Scholar
  5. 5.
    Lu-Emerson C, Eichler AF. Brain Metastasis. Continuum. 2012;18(2):295–311.PubMedGoogle Scholar
  6. 6.
    Arvold ND, Lee EQ, Mehta MP, Margolin K, Alexander BM, Lin NU, Anders CK, Soffietti R, Camidge DR, Vogelbaum MA, Dunn IF, Wen PY. Updates in the management of brain metastases. Neuro-Oncology. 2016;18(8):1043–65.  https://doi.org/10.1093/neuonc/now127.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Helfer JL, Wen PY, Blakeley J, Gilbert MR, Armstrong TS. Report of the jumpstarting brain tumor drug development coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD). Neuro-Oncology. 2016;18(suppl 2):ii26–36.  https://doi.org/10.1093/neuonc/nov270.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Walbert T, Mendoza TR, Vera-Bolanos E, Acquaye A, Gilbert MR, Armstrong TS. Symptoms and socio-economic impact of ependymoma on adult patients: results of the adult Ependymoma outcomes project 2. J Neuro-Oncol. 2015;121(2):341–8.  https://doi.org/10.1007/s11060-014-1638-4.CrossRefGoogle Scholar
  9. 9.
    Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, Yu J, Ngai C. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States. J Med Econ. 2017;20(1):54–62.  https://doi.org/10.1080/13696998.2016.1225577.CrossRefPubMedGoogle Scholar
  10. 10.
    Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: CM M, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949. p. 191 e205.Google Scholar
  11. 11.
    Wong J, Hird A, Kirou-Mauro A, Napolskikh J, Chow E. Quality of life in brain metastasis radiation trials : a literature review. Curr Oncol Rep. 2008;15(5):25–45.Google Scholar
  12. 12.
    Hutchison TA, Boyd NF, Feinstein AR. Scientific problems in clinical scales, as demonstrated in the Karnofsky index of performance status. J Chronic Dis. 1979;32(661):e6.Google Scholar
  13. 13.
    Witgert ME, Meyers CA. Neurocognitive and quality of life measures in patients with metastatic brain disease. Neurosurg Clin N Am. 2011;22:79–85.CrossRefGoogle Scholar
  14. 14.
    Kepka LT-SD, Osowiecka K, Sprawka A, Trąbska-Kluch B, Czeremszynska B. Quality of life after whole brain radiotherapy compared with radiosurgery of the tumor bed: results from a randomized trial. Clin Transl Oncol. 2018;20(2):150–9.  https://doi.org/10.1007/s12094-017-1703-5.CrossRefPubMedGoogle Scholar
  15. 15.
    Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS. Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. Neuro-Oncology. 2016;18(Suppl 2):ii13–20.  https://doi.org/10.1093/neuonc/nov291.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Taphoorn MJ, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, Stupp R, Mirimanoff RO, van den Bent MJ, Bottomley A, Group EQoL, Brain Cancer N, Radiotherapy G. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2010;46(6):1033–40.  https://doi.org/10.1016/j.ejca.2010.01.012.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Dirven L, van den Bent MJ, Bottomley A, van der Meer N, van der Holt B, Vos MJ, Walenkamp AM, Beerepoot LV, Hanse MC, Reijneveld JC, Otten A, de Vos FY, Smits M, Bromberg JE, Taal W, Taphoorn MJ, Dutch Neuro-Oncology G. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Eur J Cancer. 2015;51(10):1321–30.  https://doi.org/10.1016/j.ejca.2015.03.025.CrossRefPubMedGoogle Scholar
  18. 18.
    Osoba D, Aarson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res. 1996;5(1):139–50.CrossRefGoogle Scholar
  19. 19.
    Armstrong TS, Gning I, Mendoza TR, Weinberg JS, Gilbert MR, Tortorice ML, Cleeland CS. Clinical utility of the MDASI-BT in patients with brain metastases. J Pain Symptom Manag. 2009;37(3):331–40.  https://doi.org/10.1016/j.jpainsymman.2008.02.011.CrossRefGoogle Scholar
  20. 20.
    Armstrong TS, Mendoza T, Gning I, Coco C, Cohen MZ, Eriksen L, Hsu MA, Gilbert MR, Cleeland C. Validation of the M.D. Anderson symptom inventory brain tumor module (MDASI-BT). J Neuro-Oncol. 2006;80(1):27–35.  https://doi.org/10.1007/s11060-006-9135-z.CrossRefGoogle Scholar
  21. 21.
    Armstrong TS, Vera-Bolanos E, Acquaye A, Gilbert MR, Mendoza TR. Impact of recall period on primary brain tumor patient's self-report of symptoms. Neurooncol Pract. 2014;1(2):55–63.  https://doi.org/10.1093/nop/npu006.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Lai JSJS, Beaumont JL, Abernethy AP, Jacobsen PB, Syrjala K, Raizer JJ, Cella D. Development of a symptom index for patients with primary brain tumors. Value Health. 2014;17(1):62–9.  https://doi.org/10.1016/j.jval.2013.11.006.CrossRefPubMedGoogle Scholar
  23. 23.
    Jakola AS, Gulati M, Gulati S, Solheim O. The influence of surgery on quality of life in patients with intracranial meningiomas: a prospective study. J Neuro-Oncol. 2012;110(1):137–44.  https://doi.org/10.1007/s11060-012-0947-8.CrossRefGoogle Scholar
  24. 24.
    Jakola AS, Gulati S, Weber C, Unsgard G, Solheim O. Postoperative deterioration in health related quality of life as predictor for survival in patients with glioblastoma: a prospective study. PLoS One. 2011;6(12):e28592.  https://doi.org/10.1371/journal.pone.0028592.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Miller JAKR, Barnett GH, Suh JH, Angelov L, Murphy ES, Vogelbaum MA, Mohammadi A, Chao ST. Quality of life following stereotactic radiosurgery for single and multiple brain metastases. Neurosurgery. 2017;81(1):147–55.  https://doi.org/10.1093/neuros/nyw166.CrossRefPubMedGoogle Scholar
  26. 26.
    Kanner AA, Bokstein F, Blumenthal DT, Ram Z. Surgical therapies in brain metastasis. Semin Oncol. 2007;34(3):197–205.  https://doi.org/10.1053/j.seminoncol.2007.03.011.CrossRefPubMedGoogle Scholar
  27. 27.
    Raco A, Pesce A, Fraschetti F, D'Andrea G, Polli FM, Acqui M, Frati A. Risk of postoperative performance status worsening after resection of lesions involving the motor pathway: a multinomial logistic regression model. J Neurol Surg A Cent Eur Neurosurg. 2018;  https://doi.org/10.1055/s-0037-1617756.CrossRefGoogle Scholar
  28. 28.
    Tsao MNRD, Wirth A, Lo SS, Danielson BL, Gaspar LE, Sperduto PW, Vogelbaum MA, Radawski JD, Wang JZ, Gillin MT, Mohideen N, Hahn CA, Chang EL. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2012;2(3):210–25.CrossRefGoogle Scholar
  29. 29.
    Andrews DWSC, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–72.CrossRefGoogle Scholar
  30. 30.
    Bragstad S, Flatebo M, Natvig GK, Eide GE, Skeie GO, Behbahani M, Pedersen PH, Enger PO, Skeie BS. Predictors of quality of life and survival following gamma knife surgery for lung cancer brain metastases: a prospective study. J Neurosurg. 2018;129(1):71–83.  https://doi.org/10.3171/2017.2.JNS161659.CrossRefPubMedGoogle Scholar
  31. 31.
    Steinmann D, Paelecke-Habermann Y, Geinitz H, Aschoff R, Bayerl A, Bolling T, Bosch E, Bruns F, Eichenseder-Seiss U, Gerstein J, Gharbi N, Hagg J, Hipp M, Kleff I, Muller A, Schafer C, Schleicher U, Sehlen S, Theodorou M, Wypior HJ, Zehentmayr F, van Oorschot B, Vordermark D. Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases. BMC Cancer. 2012;12(283):283.  https://doi.org/10.1186/1471-2407-12-283.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Wong E, Rowbottom L, Tsao M, Zhang L, McDonald R, Danjoux C, Barnes E, Chan S, Chow E. Prognostic value of pre- and post-treatment health-related quality of life in predicting survival of patients with brain metastases. CNS Oncol. 2017;6(2):119–29.  https://doi.org/10.2217/cns-2016-0020.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Edelstein K, Richard NM, Bernstein LJ. Neurocognitive impact of cranial radiation in adults with cancer: an update of recent findings. Curr Opin Support Palliat Care. 2017;11(1):32–7.  https://doi.org/10.1097/SPC.0000000000000255.CrossRefPubMedGoogle Scholar
  34. 34.
    Pruit AA. Epidemiology, treatment, and complications of central nervous metastases. Continuum Neuro Oncol. 2017;23(6):1580–600.Google Scholar
  35. 35.
    Armstrong TSCS, Bolanos EV, Gilbert MR, Kang DH. Risk factors for fatigue severity in primary brain tumor patients. Cancer. 2010;116(11):2707–15.  https://doi.org/10.1002/cncr.25018.CrossRefPubMedGoogle Scholar
  36. 36.
    Walbert T. Palliative care, end-of-life care, and advance care planning in neuro-oncology. Continuum. 2017;23(6, Neuro-oncology):1709–26.  https://doi.org/10.1212/CON.0000000000000538.CrossRefPubMedGoogle Scholar
  37. 37.
    Struik K, Klein M, Heimans JJ, Gielissen MF, Bleijenberg G, Taphoorn MJ, Reijneveld JC, Postma TJ. Fatigue in low-grade glioma. J Neuro-Oncol. 2009;92(1):73–8.  https://doi.org/10.1007/s11060-008-9738-7.CrossRefGoogle Scholar
  38. 38.
    Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI. NCCN clinical practice guidelines cancer-related fatigue. J Natl Compr Cancer Netw. 2010;8(8):904–31.CrossRefGoogle Scholar
  39. 39.
    Lowe SS, Danielson B, Beaumont C, Watanabe SM, Baracos VE, Courneya KS. Associations between objectively measured physical activity and quality of life in cancer patients with brain metastases. J Pain Symptom Manag. 2014;48(3)CrossRefGoogle Scholar
  40. 40.
    Tanay MAL, Armes J, Ream E. The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: a qualitative thematic synthesis. Eur J Cancer Care. 2017;26(5)  https://doi.org/10.1111/ecc.12443.CrossRefGoogle Scholar
  41. 41.
    Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL, for the Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359–67.  https://doi.org/10.1001/jama.2013.2813.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67.  https://doi.org/10.1200/JCO.2013.54.0914.CrossRefPubMedGoogle Scholar
  43. 43.
    Brahmer JR, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Zhang J, Lubiniecki GM, Deitz AC, Rangwala R, Reck M. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 2017;18(12):1600–9.  https://doi.org/10.1016/S1470-2045(17)30690-3.CrossRefPubMedGoogle Scholar
  44. 44.
    Bordoni R, Ciardiello F, von Pawel J, Cortinovis D, Karagiannis T, Ballinger M, Sandler A, Yu W, He P, Matheny C, Felizzi F, Rittmeyer A. Patient-reported outcomes in OAK: a phase III study of atezolizumab versus docetaxel in advanced non-small-cell lung cancer. Clin Lung Cancer. 2018;19(5):441–449 e444.  https://doi.org/10.1016/j.cllc.2018.05.011.CrossRefPubMedGoogle Scholar
  45. 45.
    Ribecco AS, Pino MS, Cipriani G, Marinozzi C, Fioretto L. Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer. Expert Rev Anticancer Ther. 2013;13(10):1181–91.  https://doi.org/10.1586/14737140.2013.837667.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Departments of Neurosurgery and NeurologyHenry Ford Health SystemDetroitUSA

Personalised recommendations